PCM
NBIX icon

Pyrrho Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Pyrrho Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.14M Buy
55,204
+29,404
+114% +$1.33M 3.21% 10
2016
Q3 		$1.31M Buy
+25,800
New +$1.28M 1.95% 14

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pyrrho Capital Management's NBIX Position: Q4 2016 in Review

Pyrrho Capital Management increased its Neurocrine Biosciences (NBIX) stake by 114% in Q4 2016, buying an estimated $1.33M and bringing the position to 55,204 shares worth $2.14M. The position accounts for 3.21% of the portfolio, ranked #10.

Pyrrho Capital Management first reported a position in NBIX in Q3 2016 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Pyrrho Capital Management held 55,204 shares of Neurocrine Biosciences worth $2.14M as of Q4 2016.
  • Pyrrho Capital Management bought 29,404 Neurocrine Biosciences shares in Q4 2016, an estimated $1.33M.
  • Neurocrine Biosciences made up 3.21% of Pyrrho Capital Management's portfolio in Q4 2016, its #10 holding.
  • Pyrrho Capital Management first reported a position in Neurocrine Biosciences in Q3 2016 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Pyrrho Capital Management's 13F filing for Q4 2016, filed 10 Feb 2017.